Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2020 / N 3

Сосудистая когнитивная дисфункция на фоне сахарного диабета. Понимание особенностей этиопатогенеза – ключ к повышению эффективности терапии
В.В. Ковальчук

References

1. Kamchatnov PR, Umarova KhYa, Chugunov A.V. Management of patients with cognitive impairment. Nervous Diseases 2015;4:18-22 (In Russian).
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-V. 5th ed. Washington, DC: APA; 2013.
3. Yakhno NN. Cognitive disorders in neurological clinics. Neurological Journal 2006;11(1):4-12 (In Russian).
4. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M; Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & Dementia 2014 Nov;10(6):844-52.
5. Zakharov VV. Cognitive impairments no dementia: classification, main causes, and treatment. Effective Pharmacotherapy 2016;1:22-31 (In Russian).
6. Friedrich MJ. New figures on global dementia cases. JAMA 2015 Oct;314(15):1553.
7. De Jong RN. The nervous system complications in diabetes mellitus, with special reference to cerebrovascular changes. The Journal of Nervous and Mental Disease 1950 Mar;111(3):181-206.
8. Mijnhout GS, Scheltens P, Diamant M, Biessels GJ, Wessels AM, Simsek S, Snoek FJ, Heine RJ. Diabetic encephalopathy: a concept in need of a definition. Diabetologia 2006 Jun;49(6):1447-8.
9. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, Craft S. Different patterns of cerebral injury in dementia with or without diabetes. Archives of Neurology 2009 Mar;66(3):315-22.
10. Mokhort TV, Mokhort EG. Cognitive impairments and diabetes mellitus: prevention and treatment. Meditsinskiye Novosti 2014;12:6-10 (In Russian).
11. Vasenina EE, Levin OS. Cognitive impairments in patients with type 2 diabetes mellitus. Effective Pharmacotherapy 2016;29:40-7 (In Russian).
12. Cox DJ, Kovatchev BP, Gonder-Frederick LA, Summers KH, McCall A, Grimm KJ, Clarke WL. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 2005 Jan;28(1):71-7.
13. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, Acampora R, Passariello N, Cacciapuoti F, Paolisso G. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006 Jul;67(2):235-40.
14. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. The Lancet. Neurology 2006 Jan;5(1):64-74.
15. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009 Apr;301(15):1565-72.
16. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group; Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Harth J. Long-term effect of diabetes and its treatment on cognitive function. The New England Journal of Medicine 2007 May;356(18):1842-52.
17. Sukhov IB. Violations of hormonal regulation of adenylate cyclase system in brain of rats with diabetes mellitus and their correction by intranasally administered insulin and serotonin [Abstract from Dissertation for the Degree of Candidate of Biological Sciences]. Saint Petersburg, 2016. (In Russian).
18. Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and Alzheimer’s disease: role of insulin signalling and therapeutic implications. International Journal Molecular Sciences 2018 Oct;19(11):3306-23.
19. Woods SC, Seeley RJ, Baskin DG, Schwartz MW. Insulin and the blood-brain barrier. Current Pharmaceutical Design 2003;9(10):795-800.
20. Apostolatos A, Song S, Acosta S, Peart M, Watson JE, Bickford P, Cooper DR, Patel NA. Insulin promotes neuronal survival via the alternatively spliced protein kinase CδII isoform. The Journal of Biological Chemistry 2012 Mar;287(12):9299-310.
21. Akintola AA, van Heemst D. Insulin, aging, and the brain: mechanisms and implications. Frontiers in Endocrinology (Lausanne) 2015 Feb;6:13.
22. Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014 Jul;63(7):2232-43.
23. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. The Lancet. Diabetes & Endocrinology 2014 Mar;2(3):246-55.
24. Strachan MW, Reynolds RM, Frier BM, Mitchell RJ, Price JF. The relationship between type 2 diabetes and dementia. British Medical Bulletin 2008;88(1):131-46.
25. Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, Hannigan CM, Purohit DP, Lesser G, Grossman HT, Haroutunian V. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008 Sep;71(10):750-7.
26. De la Monte SM, Chen GJ, Rivera E, Wands JR. Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cellular and Molecular Life Sciences 2003 Dec;60(12):2679-91.
27. Kahn AM, Husid A, Allen JC, Seidel CL, Song T. Insulin acutely inhibits cultured vascular smooth muscle cell contraction by a nitric oxide synthase-dependent pathway. Hypertension (Dallas, Tex.: 1979) 1997 Oct;30(4):928-33.
28. Bhamra MS, Ashton NJ. Finding a pathological diagnosis for Alzheimer’s disease: are inflammatory molecules the answer? Electrophoresis 2012 Dec;33(24):3598-607.
29. Fishel MA, Watson G, Montine T, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. Hyperinsulinemia provokes synchronous increases in central inflammation and β-amyloid in normal adults. Archives of Neurology 2005 Oct;62(10):1539-44.
30. Zhao WQ, De Felice FG, Fernandez S, Chen H, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. Amyloid beta oligomers induce impairment of neuronal insulin receptors. The FASEB Journal 2008;22:246-60.
31. Akash MSH, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. Journal of Cellular Biochemistry 2013 Mar;114(3):525-31.
32. Erickson MA, Hansen K, Banks WA. Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine. Brain, Behavior, and Immunity 2012 Oct;26(7):1085-94.
33. Kalaria RN. Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease. Nature Reviews. Neurology 2009 Jun;5(6):305-6.
34. Suslina ZA, Tanashyan MM. Antithrombotic therapy in angioneurology. Moscow: Meditsinskaya Kniga; 2004. 110 p. (In Russian).
35. Tanashyan MM, Domashenko MA. Secondary drug prevention of ischemic stroke. Consilium Medicum 2006;8(8):86-91 (In Russian).
36. Kovalchuk VV. Secondary prevention of strokes as an integral part of general rehabilitation process. Effective Pharmacotherapy 2017;19:52-61 (In Russian).
37. Kovalchuk VV, Barantsevich ER. Cognitive impairments in vascular diseases of the brain. Features of etiopathogenesis, diagnosis and therapy. Effective Pharmacotherapy 2018;(1):10-4 (In Russian).
38. Balakumar P, Nyo YH, Renushia R, Raaginey D, Oh AN, Varatharajan R, Dhanaraj SA. Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel? Pharmacological Research 2014 Sep;87:144-50.
39. Starchina YuA, Zakharov VV. Neurological complications of diabetes mellitus. Effective Pharmacotherapy 2019;15(19):32-9 (In Russian).
40. Nakamura T, Uchiyama S, Yamazaki M, Iwata M. Effects of dipiridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma. Cerebrovascular Diseases (Basel, Switzerland) 2002;14(3-4):234-8.
41. Weisbrot-Lefkowitz M, Reuhl K, Perry B, Chan PH, Inouye M, Mirochnitchenko O. Overexpression of human glutathione peroxidase protects transgenic mice against focal cerebral ischemia/reperfusion damage. Brain Research. Molecular Brain Research 1998 Jan;53(1-2):333-8.
42. Bogolepova AN. Management of comorbidity: patients with cerebrovascular disease, hypertension and diabetes. Nervous Diseases 2018;4:15-20 (In Russian).
43. Massaro M, Scoditti E, Carluccio MA, Pellegrino M, Calabriso N, Storelli C, Martines G, De Caterina R. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Journal of Thrombosis and Haemostasis 2013 Feb;109(2):280-9.
44. Folstein M, Folstein S, McHugh P. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975 Nov;12(3):189-98.
45. Nasreddine Z, Phillips N, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 2005 Apr;53(4):695-9.
46. House A, Dennis M, Hawton K, Warlow C. Methods of identifying mood disorders in stroke patients: experience in the Oxfordshire Community Stroke Project. Age and Ageing 1989 Nov;18(6):371-9.
47. Hickie I, Lloyd A, Wakefield D, Parker G. The psychiatric status of patients with the chronic fatigue syndrome. The British Journal of Psychiatry 1990 Apr;156:534-40.
48. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32(1):50-5.
49. Kovalchuk VV. Efficacy and safety of midocalm in early recovery period of stroke. SS Korsakov Journal of Neurology and Psychiatry 2013;4:35-40 (In Russian).
50. Bergner M, Bobbitt R, Carter W, Gilson B. The sickness impact profile: development and final revision of a health status measure. Medical Care 1981 Aug;19(8):787-805.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]